Is Elevation Oncology, Inc. (ELEV) a Buy, Sell, or Hold?
NASDAQ : ELEV
Elevation Oncology, Inc.
$0.365 USD
-$0.01 (-2.12%)
- Volume
- 4.82M
- Average Volume
- 1.35M
- Market Capitalization
- $21.63M
- P/E Ratio
- -0.47
- Dividend Yield
- 0.00%
- Price Target
- $9.00
- Year High
- $3.09
- Year Low
- $0.22
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $21.21
Company Overview
NASDAQ
Joseph J. Ferra Jr.
Biotechnology
Healthcare
ELEV
34
US
USD
Liquidity Metrics
0.52
21.21
21.21
11.07
0.00
Sales & Valuation
-$
0.00
0.35
-0.59
-0.63
Profitability
-$0.78
-$44.48M
0.00%
0.00%
-77.48%
-46.52%
P/E Metrics
-0.47
-0.02
-0.02
Analyst Price Target & Rating
$9.00
$10.00
$8.00
0/5
12 Analysts
-95.94%
Financial Health Scores
-4.75
1/9
$77.96M
$82.22M
$35.49M
-$47.88M
Key Metrics (TTM)
$3.3M
0.00
-0.08
21.21
-77.48%
-49.04%
-212.79%
-168.14%
-8501 days
Company Executives
| Name | Title |
|---|---|
| Tammy Furlong | Chief Financial Officer & Secretary |
| Valerie Malyvanh Jansen | Chief Medical Officer |
| Biren Shah | Senior Vice President of Business & Corporate Development |
| Robert C. Yang | Senior Vice President & General Counsel |
| Ryan Bloomer | Senior Vice President of Technical Operations |
| Joseph J. Ferra Jr. | Chief Executive Officer, President & Director |
Poll Results
No votes yet today — be the first to share your view!
About Elevation Oncology, Inc. (NASDAQ:ELEV) Stock
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York. ...
Frequently Asked Questions
-
What is the current Elevation Oncology, Inc. (ELEV) stock price?
-
Elevation Oncology, Inc.(NASDAQ:ELEV) stock price is $0.365 in the last trading session. During the trading session, ELEV stock reached the peak price of $3.09 while $0.221 was the lowest point it dropped to. The percentage change in ELEV stock occurred in the recent session was --2.12% while the dollar amount for the price change in ELEV stock was -$0.01.
-
ELEV's industry and sector of operation?
-
The NASDAQ listed ELEV is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ELEV?
-
Tammy Furlong | Chief Financial Officer & Secretary
Valerie Malyvanh Jansen | Chief Medical Officer
Biren Shah | Senior Vice President of Business & Corporate Development
Robert C. Yang | Senior Vice President & General Counsel
Ryan Bloomer | Senior Vice President of Technical Operations -
How many employees does ELEV have?
-
Number of ELEV employees currently stands at 34. ELEV operates from 888 Seventh Avenue, Boston, NY 10106, US.
-
Link for ELEV official website?
-
Official Website of ELEV is: https://elevationoncology.com
-
How do I contact ELEV?
-
ELEV could be contacted at phone #716 371 1125 and can also be accessed through its website. ELEV operates from 888 Seventh Avenue, Boston, NY 10106, US.
-
How many shares of ELEV are traded daily?
-
The average number of ELEV shares traded daily for last 3 months was 1.35M.
-
What is the market cap of ELEV currently?
-
The market value of ELEV currently stands at $21.63M with its latest stock price at $0.365